Drugs / Zebetuzumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07208981 | Aug 2025 → Jun 2028 expected | marginal zone lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zebetuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07208981 ↗ |